- Home
- CROX vs ITCI Comparison
CROX vs ITCI Comparison
Compare CROX & ITCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CROX
- ITCI
- Stock Information
- Founded
- CROX 1999
- ITCI 2002
- Country
- CROX United States
- ITCI United States
- Employees
- CROX N/A
- ITCI N/A
- Industry
- CROX Shoe Manufacturing
- ITCI Biotechnology: Pharmaceutical Preparations
- Sector
- CROX Consumer Discretionary
- ITCI Health Care
- Exchange
- CROX Nasdaq
- ITCI Nasdaq
- Market Cap
- CROX 8.3B
- ITCI 8.0B
- IPO Year
- CROX 2006
- ITCI N/A
- Fundamental
- Price
- CROX $110.23
- ITCI $85.96
- Analyst Decision
- CROX Buy
- ITCI Strong Buy
- Analyst Count
- CROX 13
- ITCI 12
- Target Price
- CROX $159.23
- ITCI $97.00
- AVG Volume (30 Days)
- CROX 1.4M
- ITCI 459.9K
- Earning Date
- CROX 10-29-2024
- ITCI 10-30-2024
- Dividend Yield
- CROX N/A
- ITCI N/A
- EPS Growth
- CROX 27.09
- ITCI N/A
- EPS
- CROX 13.79
- ITCI N/A
- Revenue
- CROX $4,072,432,000.00
- ITCI $564,526,000.00
- Revenue This Year
- CROX $6.15
- ITCI $46.60
- Revenue Next Year
- CROX $5.33
- ITCI $37.06
- P/E Ratio
- CROX $8.09
- ITCI N/A
- Revenue Growth
- CROX 3.17
- ITCI 54.31
- 52 Week Low
- CROX $74.00
- ITCI $46.10
- 52 Week High
- CROX $165.32
- ITCI $84.89
- Technical
- Relative Strength Index (RSI)
- CROX 29.55
- ITCI 73.36
- Support Level
- CROX $129.69
- ITCI $75.57
- Resistance Level
- CROX $139.96
- ITCI $79.46
- Average True Range (ATR)
- CROX 4.22
- ITCI 2.42
- MACD
- CROX -2.54
- ITCI 0.60
- Stochastic Oscillator
- CROX 6.51
- ITCI 88.13
About CROX Crocs Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company include the Americas, Asia Pacific, and EMEA.
About ITCI Intra-Cellular Therapies Inc.
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.